Soriot also highlighted to performance of Farxiga (dapagliflozin), AZ's SGLT2 inhibit for diabetes, heart failure and chronic ... new HER2 drug Enhertu (trastuzumab deruxtecan) almost doubling ...

The decision covers the use of Enhertu (trastuzumab deruxtecan ... in England and Wales.” At the heart of the company’s concern is NICE’s use of a disease severity modifier, introduced ...

on behalf of the Pediatric Heart Failure & Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Heart failure is a major health concern, especially for aging populations—it significantly increases mortality rates, and ...

A protocol for transitioning patients with heart failure and a left ventricular assist device to a stepdown unit from the ICU ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Heart failure is a major health concern, especially for aging populations-it significantly increases mortality rates, and severely impacts quality of life for those affected.

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...